Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. - Wikidata - wikimedia - TriplyDB

Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.

Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.

http://www.wikidata.org/entity/Q43947607

about

The clinical efficacy of artemether/lumefantrine (Coartem)Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar Artemisinin-based combination therapy for treating uncomplicated malaria Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania Plasmodium falciparum drug resistance in Angola Temporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal Kenya Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial An open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania Influence of rapid malaria diagnostic tests on treatment and health outcome in fever patients, Zanzibar: a crossover validation study Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-infer Experience of safety monitoring in the context of a prospective observational study of artemether-lumefantrine in rural Tanzania: lessons learned for pharmacovigilance reporting.Combining individual patient data and aggregate data in mixed treatment comparison meta-analysis: Individual patient data may be beneficial if only for a subset of trials.The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda.Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda.Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa.Malaria: uncomplicated, caused by Plasmodium falciparum.Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria.Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children.In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations.Treatment with coartem (artemether-lumefantrine) in Papua New Guinea Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved Tool Different mutation patterns of Plasmodium falciparum among patients in Jimma University Hospital, Ethiopia.Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.Emerging artemisinin resistance in the border areas of Thailand.Malaria: an update on current chemotherapy.Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate dispersible tablets in paediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase II, multicentric, open-label study.Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children.Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo The usefulness of rapid diagnostic tests in the new context of low malaria transmission in Zanzibar Multiple genetic backgrounds of the amplified Plasmodium falciparum multidrug resistance (pfmdr1) gene and selective sweep of 184F mutation in Cambodia Fixed dose artesunate amodiaquine - a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine.Discovery, mechanisms of action and combination therapy of artemisinin

P2860

Q21034141-561E2C9B-7DEE-4AF7-8EFA-0B852DF6F484 Q21143739-AF959C70-A63F-4A7F-9BBC-A6968FB64022 Q22061782-EF81727A-D70C-4DC5-8AEF-C88AA82257F1 Q24241785-0D531DAE-8B50-49B3-8583-5883F88E95C3 Q26820807-6BA4F216-99C4-43F4-9E19-AA260863E39B Q28075079-E97C778B-CC1A-4F4D-BE21-E4B6076EB34F Q28125914-41D0BE2F-3B21-474F-B1CC-A312F03B3F8D Q28469217-4F6E632A-E860-4C08-BBD7-840E7B2E4F28 Q28473004-8ECA3AA7-199F-4F1E-BD6D-3BA32D119D20 Q28475232-CE51E73B-0AB9-4958-96F4-51F89DB05297 Q28475325-00797B74-3C2F-4992-86F0-C0A64C6E9A16 Q28691396-44E9C27A-2F09-4A6B-BCC1-C15C6EEBAD85 Q30396779-93CE4475-FF8D-4407-9EFA-E8EDE6621F5E Q30567158-D30A878C-B9A0-49F0-8015-707A26088D82 Q30936416-23BE45FE-FE35-442F-B1C0-D5E47D2FED0E Q33251914-4A6C7035-D7DC-417F-B54B-FE8699600A3A Q33342827-98E97BDE-B4C4-4DE1-99FB-85FB231DD361 Q33399342-C8EF5EDB-A252-41E2-840A-33C7EA7031CE Q33446846-E1DD2470-ED8F-42B9-A72A-8AAE2F131CEA Q33635019-55CBCCD3-A06D-4E37-BD77-A52FCF7B0C10 Q33650896-145F137A-7A86-4FB0-A404-A726E2BF93D8 Q33676088-731F98D3-5264-4C0C-B440-77412699EEBC Q33723453-30EFA7C0-B003-4A4F-BBD9-F69BAF0F3647 Q33749688-6830D05F-B870-4063-B235-A816BF039189 Q33826359-0D2942FE-1863-4371-968E-B9F4A4D6CE6D Q33875677-5C27E714-93E8-443A-8057-8ABCCC1EA424 Q34068703-7D83A1AC-4FFF-4D74-889F-B166BA7BF628 Q34281680-5A779DD9-A5EF-43ED-B5CD-CE6C9C4E07E9 Q34290067-68BDF911-F508-47DB-AF9B-84C51977EC8B Q34343530-102AC9FB-BAE1-4988-B825-701CB55F65E5 Q34433106-6AC24EF1-4A89-4C70-88AE-129AF00ACC3D Q34503134-27045481-95CE-4925-A8E7-7EBF482AC76A Q34597550-C8106AD1-13EE-4E5A-B4C7-7792BF27F2DB Q34648820-84D9A964-45DE-4AE3-ADB7-62D04957E2F8 Q34662803-2751B5BE-FB9C-4301-9CBB-813B8DCA9B08 Q34719926-E23066E8-E8B3-4438-B0D2-B4C3ABE7983E Q34984133-97138B23-75D0-4BDC-8A28-B43E2B86FB53 Q34986023-A4AA070A-5B23-492B-B14A-87AAF16504C0 Q34996451-15E53D03-6862-483A-BDBC-0F56AE7F4BF4 Q35006418-40E23166-A9DD-4F14-B7D5-641B29FE0A44

P2860

Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.

http://www.wikidata.org/entity/Q43947607

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Efficacy of artesunate plus am ...... malaria in Zanzibar, Tanzania.

@en

Efficacy of artesunate plus am ...... malaria in Zanzibar, Tanzania.

@nl

type

label

Efficacy of artesunate plus am ...... malaria in Zanzibar, Tanzania.

@en

Efficacy of artesunate plus am ...... malaria in Zanzibar, Tanzania.

@nl

prefLabel

Efficacy of artesunate plus am ...... malaria in Zanzibar, Tanzania.

@en

Efficacy of artesunate plus am ...... malaria in Zanzibar, Tanzania.

@nl

P1433

Q43947607-212DFBF8-B69F-4643-A60F-2D3034E71742

P1476

Q43947607-E66E6469-0A48-4DC1-B15F-2D5E5608DFB9

P2093

Q43947607-226CCE95-0B40-4B65-B417-90E4499F633F

Q43947607-71441CFF-D339-4FA7-9748-2449787F3457

Q43947607-7DC66228-0DF6-47A5-9002-2593283AF0EA

Q43947607-9B5B2696-1537-4A22-A1F1-81CF85BB5F1D

Q43947607-B7EB877A-A808-406C-ABCC-025CAE8CDF84

Q43947607-FADDCF2A-EEF7-4650-ACC5-200017697846

P2860

Q43947607-03C76763-07CF-44DE-8F26-BED1370F5C3F

Q43947607-23A2F58E-CEF1-4281-8AE7-B5FECB183333

Q43947607-26C264C6-20E3-42B2-90EF-F0CE53F80F9B

Q43947607-423C3511-DBF8-4E79-9263-B3CF1F08ADE8

Q43947607-429E82EE-FAE8-46F5-8482-E8BFE16D7313

Q43947607-4E32F7BE-65C9-4575-8388-42142918A9B1

Q43947607-50A2EEA2-79EA-435F-A7A7-DD1EA0C6082E

Q43947607-55906ED4-ABD4-461B-9BCC-48870EECD966

Q43947607-6B21A6CC-D689-4387-9C7E-108E22009305

Q43947607-79A3B6F0-8830-49B5-AF4B-E83A04D5BCFE

P304

Q43947607-B2652C1D-DA0E-45A6-9A9B-5CAF03E62301

P31

Q43947607-C1AAFD5B-8D43-4043-B139-FE883859F646

P356

Q43947607-12FA6F02-3033-420B-8DD4-06174289C537

P407

Q43947607-68272282-A63C-4706-8E6F-89244D7C3184

P433

Q43947607-EF87A42E-19D3-46BC-A2DF-10E8D97466F5

P478

Q43947607-5BAD13E8-EBA5-49E7-BE50-5366FF2F10CB

P50

Q43947607-5DFEEFAA-BEF0-415C-807B-04B7C448A346

Q43947607-910EC7C0-33BC-4F61-B0C6-028ED180DCB9

Q43947607-AB58DDEF-5D9A-460A-A8DE-ED8C5B0C7C9D

P577

Q43947607-6138A787-457E-411C-8FFD-9F83677A90E6

P5875

Q43947607-79999FAF-060E-4B02-A489-D633C44819E8

P698

Q43947607-FDED1653-2FEE-44D4-BBEB-C19BC0AA503D

P921

Q43947607-1FEDFBBA-D92F-4844-B821-6BBE6099DB36

Q43947607-819719F0-4A87-4976-8DE3-97353C9AF0C7

Q43947607-862B3A24-2C1D-459A-A372-0338C5BC1F01

Q43947607-8F81A339-9685-4A2C-B31E-D7DFC5550E68

Q43947607-D29B493E-BC85-4D82-94D0-005C88B6F7B9

P356

P1433

Clinical Infectious Diseases

P1476

Efficacy of artesunate plus am ...... malaria in Zanzibar, Tanzania.

@en

P2093

Abdullah S Ali

http://www.w3.org/2001/XMLSchema#string

Andreas Mårtensson

http://www.w3.org/2001/XMLSchema#string

Christin Sisowath

http://www.w3.org/2001/XMLSchema#string

J Pedro Gil

http://www.w3.org/2001/XMLSchema#string

Johan Strömberg

http://www.w3.org/2001/XMLSchema#string

Mwinyi I Msellem

http://www.w3.org/2001/XMLSchema#string

P2860

A molecular marker for chloroquine-resistant falciparum malaria.

Estimating the needs for artesunate-based combination therapy for malaria case-management in Africa.

Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.

The origins of antimalarial drug resistance.

In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up.

Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum.

The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin.

Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years.

Averting a malaria disaster.

Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study.

P304

1079-1086

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/444460

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P50

Scott M Montgomery

Anders Björkman

P577

2005-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7598642

http://www.w3.org/2001/XMLSchema#string

P698

16163624

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium falciparum